Immunovia Launches Pancreassure, Faces Reimbursement Hurdles

Immunovia AB has successfully launched its Pancreassure test, marking a significant shift from a development-focused company to a commercial entity. The Pancreassure test, praised for its high sensitivity and specificity, is designed to aid in screening high-risk individuals for pancreatic cancer. The company has achieved crucial reimbursement milestones, including obtaining a billing code and a favorable Medicare reimbursement rate of $897.

Despite these positive steps, Immunovia is currently navigating the complexities of commercial adoption. Widespread insurer coverage, particularly from Medicare and commercial payers, has not yet been secured, which is essential for broad market penetration. Revenue generation from the Pancreassure test is projected to be delayed, with substantial financial returns not expected until 2026.

The company is actively building clinical utility evidence and has engaged key opinion leaders and ten leading pancreatic cancer centers that have begun implementing the test. While Immunovia's cash position has been strengthened, increased spending on commercial activities is anticipated. The current sales efforts rely on management, highlighting a need to scale operations for future growth.